Targeting ferroptosis resistance re-sensitizes metastatic HR+ HER2- breast cancer to palbociclib-hormone therapy
RNA-seq (gene expression) · human · 21 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Breast cancerThis series is part of our curated briefing on it.
- Samples
- 21 samples: 7 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Targeting ferroptosis resistance resensitizes metastatic HR(+)HER2(-) breast cancer cells to palbociclib-hormone therapyCancer communications (London, England) · 2025
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE270021_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1124870 and SRA study SRP514315. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 21 samples.
How we read this: 7 replicated groups read from 21 sample titles; they account for 21 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8332900 CAMA, Untreated, biol rep1 CAMA, Untreated, biol
- GSM8332901 CAMA, Untreated, biol rep2 CAMA, Untreated, biol
- GSM8332902 CAMA, Untreated, biol rep3 CAMA, Untreated, biol
- GSM8332903 CAMA, Day5, biol rep1 CAMA, Day5, biol
- GSM8332904 CAMA, Day5, biol rep2 CAMA, Day5, biol
- GSM8332905 CAMA, Day5, biol rep3 CAMA, Day5, biol
- GSM8332906 CAMA, Day20, biol rep1 CAMA, Day20, biol
- GSM8332907 CAMA, Day20, biol rep2 CAMA, Day20, biol
- GSM8332908 CAMA, Day20, biol rep3 CAMA, Day20, biol
- GSM8332909 T47D, Untreated, biol rep1 T47D, Untreated, biol
- GSM8332910 T47D, Untreated, biol rep2 T47D, Untreated, biol
- GSM8332911 T47D, Untreated, biol rep3 T47D, Untreated, biol
- GSM8332912 T47D, Day5, biol rep1 T47D, Day5, biol
- GSM8332913 T47D, Day5, biol rep2 T47D, Day5, biol
- GSM8332914 T47D, Day5, biol rep3 T47D, Day5, biol
- GSM8332915 T47D, Day20, biol rep1 T47D, Day20, biol
- GSM8332916 T47D, Day20, biol rep2 T47D, Day20, biol
- GSM8332917 T47D, Day20, biol rep3 T47D, Day20, biol
- GSM8332918 T47D, Resistant, biol rep 1 T47D, Resistant, biol
- GSM8332919 T47D, Resistant, biol rep 2 T47D, Resistant, biol
- GSM8332920 T47D, Resistant, biol rep 3 T47D, Resistant, biol
- GSE104675 Role for the Transcriptional Activator ZRF1 in Breast Cancer Progression and Endocrine Resistance 6 samples same disease briefing · shares resistance
- GSE104193 Hypoxia-mediated translational activation of ITGB3 in breast cancer cells enhances TGF-β signalling and malignant features in vitro and in vivo 32 samples same disease briefing
- GSE10885 An integromic analysis reveals that metaplastic carcinomas are distinct from basal-like tumors. 244 samples same disease briefing
- GSE10886 A Supervised Risk Predictor of Breast Cancer Based on Biological Subtypes 226 samples same disease briefing
- GSE11121 The humoral immune system has a key prognostic impact in node-negative breast cancer 200 samples same disease briefing
- GSE249573 Cancer-stromal cell interactions in breast cancer brain metastases induce glycocalyx-mediated resistance to HER2-targeting therapies [RNA-seq] 40 samples shares her2, resistance, targeting
- GSE231525 DUSP6 inhibition overcomes Neuregulin/HER3-driven therapy resistance in HER2+ breast cancer [BT474] 12 samples shares her2, resistance, therapy
- GSE230326 BRD8 is a therapeutic vulnerability for overcoming resistance to dual ER/HER2 blockade therapy in HR+/HER2+ breast cancer [bulkRNA-seq] 12 samples shares her2, resistance, therapy
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.